<i id='7B27001405'><strike id='7B27001405'><tt id='7B27001405'><pre id='7B27001405'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
ChatGPT in medicine: STAT answers readers' burning questions 
What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+ 
Medical records are filled with copy 
Does Medicare's free annual wellness visit do any good? 
Supreme Court strikes down use of affirmative action 
Prosecutors seek bail revocation for FTX founder Sam Bankman 
In Memoriam: Notable people who died in 2023 
Climate activists disrupt London Pride march to protest corporate sponsorship
In Memoriam: Notable people who died in 2023
Does Medicare's free annual wellness visit do any good? 
As demand for Covid shots wanes, Moderna seeks its next success 
'Cuddling' is just what the doctor ordered for a 200 
In age of alternative facts, a scholarly course on calling out crap 
Calls for Trump's election interference trial to be televised part of long debate 
Affirmative action in medical school literally saved lives 
